The European Union has approved a new type of treatment for advanced forms of lung cancer. It is a combination of Avastin and Tarceva, developed and produced by the Swiss pharmaceutical company Roche.
The new therapy is addressed to patients with inoperable tumors, developed metastases and those whose symptoms recurred after other therapies.
The European officials gave green light for this combination of Avastin and Tarceva, following a study which showed that the mortality rate and the disease evolution dropped to 46% in the case of patients treated by this method.
It is natural wholesale sildenafil and nothing to worry about it. Moreover, ED medicines come at the first potion that are female viagra samples not accredited by the FDA. Also, Vardenafil causes no or minimal visual disturbance, which is a common side effect of generic viagra mastercard . The treatment is suitable for most apart from users already taking or planning to take nitrate based generic cialis australia medications.
According to statistics, 23,000 people are diagnosed with lung cancer every year in Europe alone.
La Roche AG is a global health-care company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics.